AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17240231 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 200
Study 15701249 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin ointment (15%) applied twice daily for 30 days
Number of subjects: 65
Study 15701249 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10% urea lotion) applied twice daily for 30 days
Number of subjects: 65
Study 12088953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1.0 mg/kg) with propofol and fentanyl (Group A)
Number of subjects: 70
Study 12088953 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 70
Study 12088953 — intervention group
Group type: COMPARATOR
Intervention: Propofol and fentanyl (Group B)
Number of subjects: 70
Study 12088953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (Group A)
Number of subjects: 70
Study 12088953 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (Ketamine)
Number of subjects: 70
Study 10489823 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaldehyde
Number of subjects: 26
Study 10489823 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 26
Study 10489823 — intervention group
Group type: EXPERIMENTAL
Intervention: Log PC20,acet/PC20,meth
Number of subjects: 26
Study 8951252 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV) after surfactant administration (100 mg/kg)
Number of subjects: 125
Study 8951252 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CV)
Number of subjects: 125
Study 2024598 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week program of exercise conditioning and behavioral counseling
Number of subjects: 201
Study 2024598 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 201
Study 6164480 — intervention group
Group type: EXPERIMENTAL
Intervention: Actinomycin D (AMD) and Vincristine (VCR) for 6 or 15 months (Group I)
Number of subjects: 188
Study 6164480 — intervention group
Group type: EXPERIMENTAL
Intervention: Actinomycin D (AMD) and Vincristine (VCR) plus Adriamycin (Reg. D) for 15 months (Groups II and III)
Number of subjects: 188
Study 6164480 — intervention group
Group type: COMPARATOR
Intervention: Actinomycin D (AMD) and Vincristine (VCR) (Reg. C) for 15 months (Groups II and III)
Number of subjects: 188
Study 6164480 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable histology (UH)
Number of subjects: 188
Study 6164480 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable histology (FH)
Number of subjects: 188
Study 6164480 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive lymph nodes
Number of subjects: 188
Study 6164480 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative lymph nodes
Number of subjects: 188
Study 31521157 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV counseling and testing (HTC) performed in family planning clinics
Number of subjects: 4389
Study 31521157 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinics with trained HIV testing providers
Number of subjects: 4389
Study 31521157 — intervention group
Group type: EXPERIMENTAL
Intervention: Public clinics versus non-public clinics
Number of subjects: 4389
Study 31521157 — intervention group
Group type: EXPERIMENTAL
Intervention: Having an HIV comprehensive care center (CCC) onsite
Number of subjects: 4389
Study 27777261 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide infusion (n=29)
Number of subjects: 57
Study 27777261 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (n=19)
Number of subjects: 57
Study 27777261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%; n=28)
Number of subjects: 57
Study 27777261 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (n=17)
Number of subjects: 57
Study 26061837 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Assess, Acknowledge, Act Sexual Assault Resistance program (resistance group)
Number of subjects: 893
Study 26061837 — intervention group
Group type: COMPARATOR
Intervention: Access to brochures on sexual assault (control group)
Number of subjects: 893
Study 22607455 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic-based resilient liner (ARL)
Number of subjects: 67
Study 22607455 — intervention group
Group type: COMPARATOR
Intervention: Conventional acrylic resin (CAR)
Number of subjects: 67
Study 21740575 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily breakfast consumption (≥3000 kJ before 1100 each day)
Number of subjects: 70
Study 21740575 — intervention group
Group type: COMPARATOR
Intervention: Extended fasting (abstaining from energy-providing nutrients until 1200 each day)
Number of subjects: 70
Study 19214934 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16927570 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Behaviour Checklist/CBCL 1 1/2‐5
Number of subjects: 280
Study 16927570 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Rating Scale for Attention‐Deficit Hyperactivity Disorder (ADHD)
Number of subjects: 280
Study 12954579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 6 mg
Number of subjects: 466
Study 12954579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 2 mg
Number of subjects: 466
Study 12954579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study 10681340 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexipafant
Number of subjects: 131
Study 10681340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 9192194 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose load
Number of subjects: 10
Study 9192194 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed load (glucose+cream)
Number of subjects: 10
Study 9192194 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipids load (cream)
Number of subjects: 10
Study 9192194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat oxidation
Number of subjects: 10
Study 8447307 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-drainage system
Number of subjects: 79
Study 8447307 — intervention group
Group type: COMPARATOR
Intervention: Open-drainage system
Number of subjects: 79
Study 8447307 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotic therapy
Number of subjects: 79
Study 2937742 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty
Number of subjects: 101
Study 2937742 — intervention group
Group type: COMPARATOR
Intervention: Coronary bypass surgery
Number of subjects: 101
Study 30073585 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab plus standard of care (SOC)
Number of subjects: 382
Study 30073585 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 382
Study 30073585 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab plus SOC
Number of subjects: 382
Study 28086005 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive therapy
Number of subjects: 156
Study 28086005 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 156
Study 28086005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 24859124 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma management education program (n=23), conducted a maximum of 3 times every 24 hours during hospitalization
Number of subjects: 43
Study 24859124 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment (Control group, n=20)
Number of subjects: 43
Study 22399764 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficient visual search
Number of subjects: 0
Study 22399764 — intervention group
Group type: EXPERIMENTAL
Intervention: Inefficient visual search
Number of subjects: 0
Study 20035529 — intervention group
Group type: EXPERIMENTAL
Intervention: Open minimally invasive parathyroidectomy
Number of subjects: 143
Study 20035529 — intervention group
Group type: COMPARATOR
Intervention: Video-assisted parathyroidectomy (MIVAP or VAPLA)
Number of subjects: 143
Study 20035529 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 143
Study 19082228 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% tea lotion
Number of subjects: 40
Study 19082228 — intervention group
Group type: COMPARATOR
Intervention: 5% zinc sulphate solution
Number of subjects: 40
Study 15930209 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (loading dose of 100 microg/kg, followed by infusions of 10-30 microg/kg per hour)
Number of subjects: 42
Study 15930209 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose infusions)
Number of subjects: 42
Study 15930209 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 42
Study 15930209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 12931804 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock-wave therapy
Number of subjects: 74
Study 12931804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 10761958 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 5878
Study 10761958 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 5878
Study 8967584 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion (18 mg/kg.h) with fentanyl (0.15 mg)
Number of subjects: 48
Study 8967584 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion (18 mg/kg.h) without fentanyl
Number of subjects: 48
Study 8967584 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion (18 mg/kg.h)
Number of subjects: 48
Study 1346599 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine tablet (5 mg), taken 1 hour after dinner from the 8th to the 18th day of the menstrual cycle.
Number of subjects: 452
Study 1346599 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 452
Study 6206318 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 to 1.0 mg/day)
Number of subjects: 25
Study 6206318 — intervention group
Group type: EXPERIMENTAL
Intervention: Meproscillarin (0.5 to 2.0 mg/day)
Number of subjects: 25
Study 6206318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 29482051 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session, tailored, indirect brief intervention
Number of subjects: 500
Study 29482051 — intervention group
Group type: COMPARATOR
Intervention: Time control condition
Number of subjects: 500
Study 26414681 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 40
Study 25087835 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-h Dyspnea Score (DS)
Number of subjects: 142
Study 25087835 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-h %FEV1
Number of subjects: 142
Study 25087835 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline DS, 3-h DS, change in DS, oxygen use at hour 3
Number of subjects: 142
Study 23318610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 72
Study 23318610 — intervention group
Group type: COMPARATOR
Intervention: Non-tourniquet
Number of subjects: 72
Study 20833939 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 39
Study 20833939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 18237682 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 105
Study 18237682 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 105
Study 15939519 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 25
Study 12658772 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg irbesartan capsule (test)
Number of subjects: 18
Study 12658772 — intervention group
Group type: COMPARATOR
Intervention: irbesartan tablet (reference)
Number of subjects: 18
Study 10619013 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined continuing medical education intervention (three interactive case audio-conferences plus chart reminders)
Number of subjects: 222
Study 7851583 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with unexplained infertility
Number of subjects: 87
Study 7851583 — intervention group
Group type: COMPARATOR
Intervention: Parous controls
Number of subjects: 87
Study 1673089 — intervention group
Group type: EXPERIMENTAL
Intervention: CQA 206‐291 (mixed D1‐D2 receptor agonist)
Number of subjects: 0
Study 1673089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7036712 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 mg cimetidine
Number of subjects: 0
Study 7036712 — intervention group
Group type: COMPARATOR
Intervention: 1,000 mg cimetidine
Number of subjects: 0
Study 7036712 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization (one week)
Number of subjects: 0
Study 31866083 — intervention group
Group type: EXPERIMENTAL
Intervention: Current HRT users
Number of subjects: 75587
Study 31866083 — intervention group
Group type: COMPARATOR
Intervention: Never users of HRT
Number of subjects: 75587
Study 31866083 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT or oral contraception use
Number of subjects: 75587
Study 31530055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration group (dry weight gradually reduced by increasing ultrafiltration volume)
Number of subjects: 64
Study 31530055 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional dialysis with routine ultrafiltration maintained)
Number of subjects: 64
Study 27059218 — intervention group
Group type: EXPERIMENTAL
Intervention: Preheating of SLIPA at 42 °C
Number of subjects: 80
Study 27059218 — intervention group
Group type: COMPARATOR
Intervention: Control group at 24 °C
Number of subjects: 80
Study 24697256 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive WM training (n = 14)
Number of subjects: 28
Study 24697256 — intervention group
Group type: COMPARATOR
Intervention: Nonadaptive low-level training (active control group, n = 14)
Number of subjects: 28
Study 24412468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5mg/d
Number of subjects: 732
Study 24412468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3.0mg/d
Number of subjects: 732
Study 24412468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 4.5mg/d
Number of subjects: 732
Study 24412468 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 4.0mg/d
Number of subjects: 732
Study 24412468 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatments
Number of subjects: 732
Study 24412468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 732
Study 22858806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/Basiliximab (Tac/Bas)
Number of subjects: 421
Study 22858806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/Mycophenolate Mofetil (Tac/MMF)
Number of subjects: 421
Study 22858806 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (Tacrolimus/Mycophenolate Mofetil/steroids)
Number of subjects: 421
Study 19203563 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (Group A)
Number of subjects: 40
Study 19203563 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (Group B)
Number of subjects: 40
Study 17577466 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30 mg
Number of subjects: 290
Study 17577466 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg
Number of subjects: 290
Study 17577466 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 70 mg
Number of subjects: 290
Study 17577466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 15172263 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating heart revascularization
Number of subjects: 70
Study 15172263 — intervention group
Group type: COMPARATOR
Intervention: Arrested heart revascularization
Number of subjects: 70
Study 11350323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.63 microg x kg(‐1))
Number of subjects: 49
Study 11350323 — intervention group
Group type: COMPARATOR
Intervention: Propofol (ED50: 3.45 mg x kg(‐1) x h(‐1), ED95: 6.68 mg x kg(‐1) x h(‐1))
Number of subjects: 49
Study 10770009 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded amalgam restorations
Number of subjects: 38
Study 10770009 — intervention group
Group type: COMPARATOR
Intervention: Nonbonded amalgam restorations (amalgapins or threaded pins)
Number of subjects: 38
Study 9346217 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP (cyclophosphamide/doxorubicin/cisplatin)
Number of subjects: 1447
Study 9346217 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 1447
Study 9346217 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (Taxol) in combination with carboplatin
Number of subjects: 1447
Study 8462317 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestodene (75 micrograms)
Number of subjects: 40
Study 8462317 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel (150 micrograms)
Number of subjects: 40
Study 4025290 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity counter (LSI Moving Activity Monitor)
Number of subjects: 80
Study 4025290 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic accelerometer (Caltrac Personal Activity Computer)
Number of subjects: 80
Study 4025290 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports of time spent in physical activity
Number of subjects: 80
Study 4025290 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity counter and electronic accelerometer
Number of subjects: 80
Study 31314569 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants receiving ≤4 fl oz daily of formula in the first month
Number of subjects: 199
Study 31314569 — intervention group
Group type: COMPARATOR
Intervention: Infants who breastfed exclusively
Number of subjects: 199
Study 31314569 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants receiving formula daily (not specified volume)
Number of subjects: 199
Study 31314569 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants receiving ≤4 fl oz daily of formula
Number of subjects: 199
Study 30145817 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline proGRP levels
Number of subjects: 1541
Study 30145817 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary endpoint (death from any cause or first hospitalization for worsening of HF)
Number of subjects: 1541
Study 30145817 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in proGRP during 6 month follow-up
Number of subjects: 1541
Study 26265372 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 987
Study 24399164 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of processing training (approximately 10 hours of computerized training)
Number of subjects: 46
Study 24399164 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 46
Study 24399164 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of processing training
Number of subjects: 46
Study 23377511 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 1.2%‐tretinoin 0.025% (CLIN/RA) gel
Number of subjects: 0
Study 23377511 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide 2.5%‐adapalene 0.1% (BPO/ADA) gel
Number of subjects: 0
Study 20207272 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-tailored interventions targeting specific problems and beliefs regarding the regimen
Number of subjects: 15
Study 20207272 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare provider interventions emphasizing benefits of compliance
Number of subjects: 15
Study 20207272 — intervention group
Group type: EXPERIMENTAL
Intervention: Group interventions including tips from patients
Number of subjects: 15
Study 19020122 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg dexamethasone (Group D1)
Number of subjects: 166
Study 19020122 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg dexamethasone (Group D2)
Number of subjects: 166
Study 19020122 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 166
Study 15741051 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil group (n=43)
Number of subjects: 166
Study 15741051 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=42)
Number of subjects: 166
Study 15741051 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (males)
Number of subjects: 166
Study 12614528 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki master
Number of subjects: 50
Study 12614528 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki practitioner
Number of subjects: 50
Study 12614528 — intervention group
Group type: COMPARATOR
Intervention: Sham Reiki
Number of subjects: 50
Study 12614528 — intervention group
Group type: COMPARATOR
Intervention: No treatment (historic control)
Number of subjects: 50
Study 10403616 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg once daily)
Number of subjects: 25
Study 10403616 — intervention group
Group type: COMPARATOR
Intervention: Felodipine (10 mg once daily)
Number of subjects: 25
Study 7720941 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (3.75 mg IM leuprolide acetate every 28 days for 6 months)
Number of subjects: 33
Study 7720941 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive (combination monophasic for 6 months)
Number of subjects: 33
Study 7720941 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination GnRH agonist and oral contraceptive (LA + OC for 6 months)
Number of subjects: 33
Study 2039640 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and alfentanil
Number of subjects: 40
Study 2039640 — intervention group
Group type: COMPARATOR
Intervention: Thiopental sodium, N2O, fentanyl, isoflurane
Number of subjects: 40
Study 2039640 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 2039640 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 40
Study 31999341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided treat-to-target strategy
Number of subjects: 230
Study 31999341 — intervention group
Group type: COMPARATOR
Intervention: Conventional treat-to-target strategy
Number of subjects: 230